KAUKAUNA, Wisc., May 22, 2018 (GLOBE NEWSWIRE) -- Nutritional supplement company MitoSynergy is pleased to announce that it has achieved several approved and pending patents, including:
- Pure Chelation Process
- Cuprous Chloride Complex Compositions and Methods of Manufacture and Use
- Chlorobis Copper (I) Complex Compositions and Methods of Manufacture and Use
Unlike other supplements that use Copper (II) as an ingredient, MitoSynergy products are the only dietary supplements on the market that feature the only bioavailable form of copper, Cunermuspir, or Copper (I) Niacin. Cunermuspir was developed to optimize the oxidization of the copper. Through its unique bioavailability, the ingredient Cunermuspir can enter the human cell and be utilized for a number of biochemical processes like ATP cycling.
MitoSynergy also recently achieved the no objection #910 approval status from the U.S. Food and Drug Administration (FDA).
"The process for submitting Copper One Niacin to the FDA as a New Dietary Ingredient (NDI) was strenuous and gave me a new confidence in other dietary ingredients that have been through the same process without objection," said Charlie Barker, CEO of MitoSynergy. "Developing this ingredient has been an incredibly complex journey of imitating the activity of plants work with copper. We are excited to provide end users and other dietary companies with a safe and bioavailable copper that may help improve energy and mental clarity and or aid with discomfort.”
For more information about MitoSynergy, www.MitoSynergy.com or contact info@mitosynergy.com.
About MitoSynergy
MitoSynergy is a nutritional supplement company bringing consumers a better quality of life. Being the world’s first Copper (I) supplement we have witnessed a direct impact on human cell energy producers the mitochondria. MitoSynergy started because of a loving uncle wanting to help his nephew that became paralyzed in his endeavors searching the world collaborating with top scientist and doctors to help his nephew the uncle stumbled across what led him to develop the world’s first Copper One Niacin.
MEDIA CONTACT:
Valeria Velasco
310-405-0357
Valeria@MarketingMaven.com
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/35293de0-15d7-402b-ae6b-df2ec44a3b5d